Acting On Peptide Bond (e.g., Thromboplastin, Leucine Amino-peptidase, Etc., (3.4)) Patents (Class 435/212)
  • Patent number: 10405567
    Abstract: A food additive for improving sensory characteristics and providing nutritional value to cereals or cereal mixture with irregular surface, which consists of collagen peptides of terrestrial and marine animal origin, the composition of which is, in % by weight, from 14% to 18% essential amino acids, from 10% to 14% aspartic acid and from 18% to 22% glycine, from 23% to 27% proline and hydroxyproline, from 9% to 13% glutamic acid, from 6% to 10% arginine, and from 6% to 10% alamine, dissolved in 5% to 50% aqueous solution, which is used as a carrier for adding ingredients, to form a uniform glossy coating on the surface of cereals or cereal mixture.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 10, 2019
    Inventor: Americo Puppo
  • Patent number: 10385381
    Abstract: This invention relates to the use of clotting compositions containing prothrombin activators to produce high quality blood serum samples for pathology and other biological assays, and to containers containing such clotting compositions, and related methods of use.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: August 20, 2019
    Inventors: Paul Masci, John De Jersey, Martin Lavin, Julie Phillips, Goce Dimeski
  • Patent number: 10262840
    Abstract: A plasma processing apparatus including: a monitor device which monitors a process quantity generated at plasma processing; a monitor value estimation unit which has monitor quantity variation models for storing change of a monitor value of the process quantity in accordance with the number of processed specimens and which estimates a monitor value for a process of a next specimen by referring to the monitor quantity variation models; and a control quantity calculation unit which stores a relation between a control quantity for controlling the process quantity of the vacuum processing device and a monitor value and which calculates the control quantity based on a deviation of the estimated monitor value from a target value to thereby control the process quantity for the process of the next specimen. Thus, stable processed results can be obtained even when variation occurs in processes.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: April 16, 2019
    Assignee: HITACHI HIGH-TECHNOLOGIES CORPORATION
    Inventors: Akira Kagoshima, Daisuke Shiraishi, Satomi Inoue, Shigeru Nakamoto, Shoji Ikuhara, Toshihiro Morisawa
  • Patent number: 10253061
    Abstract: The invention relates to a method for enzymatically synthesizing an (oligo)peptide, comprising coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine, wherein the coupling is carried out in a fluid comprising water, and wherein the coupling is catalyzed by a subtilisin BPN? variant or a homolog thereof, which comprises the following mutations compared to subtilisin BPN? represented by SEQUENCE ID NO: 2 or a homolog sequence thereof: a deletion of the amino acids corresponding to positions 75-83; a mutation at the amino acid position corresponding to S221, the mutation being S221C or S221 selenocysteine; preferably a mutation at the amino acid position corresponding to P225 wherein the amino acid positions are defined according to the sequence of subtilisin BPN? represented by SEQUENCE ID NO: 2. Further, the invention relates to an enzyme suitable for use as a catalyst in a method of the invention.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: April 9, 2019
    Assignee: ENZYPEP B.V.
    Inventors: Peter Jan Leonard Mario Quaedflieg, Timo Nuijens, Jan Metske Van Der Laan, Dirk Barend Janssen, Ana Toplak, Bian Wu
  • Patent number: 10221400
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: March 5, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 10106596
    Abstract: Disclosed is a process for preparing proteinaceous materials. The process comprises solubilizing fibrous protein by contacting it with an alkaline solution, ageing the resulting mixture to form a homogenous solution, and coagulating the resulting solution to form the proteinaceous material. The proteinaceous materials may be produced as, for example, fibers, films, sheets, coatings, particles, shapes, foams or composites.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: October 23, 2018
    Assignee: FARMCORP WOOLS LIMITED
    Inventor: Mirshahin Seyed Saleh
  • Patent number: 10081782
    Abstract: Low-pH automatic dishwashing detergent composition comprising an endoprotease having an isoelectric point from about 4 to about 9 and wherein the composition has a pH as measured in 1% weight aqueous solution at 25° C. of from about 5 to about 7.5.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 25, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Alan Thomas Brooker, Philip Frank Souter, Colin Ure, Craig Adam Wilkinson, Lindsay Suzanne Bewick
  • Patent number: 10047134
    Abstract: The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called ‘critical nutrient ratio’ for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 14, 2018
    Assignee: Biocon Limited
    Inventors: Sanjay Tiwari, Gourav Awasthi, Gokul Jothiraman, Arun Chandavarkar
  • Patent number: 9944682
    Abstract: We describe the rational structure-based design of monomeric and dimeric forms of a nanobody-enhanced GFP (termed vsfGFP) that demonstrates ˜1.3-fold higher brightness than sfGFP in a monomeric form and ˜2.5-fold higher brightness in a dimeric form. These new vsfGFP variants demonstrate high stability and brightness in both bacterial and eukaryotic cells and are thus ideal for in vivo imaging applications. The combination of higher brightness, facile folding, stable expression, and tunable dimerization makes them ideal partners in essentially all in vitro applications already described for fluorescent proteins, including antibody fusion-based molecular probes, for which the higher brightness and tunable dimerization provide distinct advantages. Furthermore, the vsfGFP variants retain folding properties of sfGFP that enable bright fluorescence in oxidizing environments such as the bacterial periplasm.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: April 17, 2018
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Swaine Chen, Majid Eshaghi
  • Patent number: 9891238
    Abstract: A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and/or activated Factor IX and/or activated Factor XII, and/or activated Factor VII and/or activated Factor X in a sample capable of being administered to humans.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: February 13, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Catherine Michalski
  • Patent number: 9732345
    Abstract: The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 15, 2017
    Assignees: Baylor College of Medicine, Texas Heart Institute
    Inventors: James F Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
  • Patent number: 9694048
    Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 4, 2017
    Assignee: BAYER HEALTHCARE, LLC
    Inventors: Maxine Bauzon, Terry Hermiston
  • Patent number: 9650621
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 16, 2017
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
  • Patent number: 9550805
    Abstract: The invention is directed to a Ca2+ precipitable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipitable tags and cassettes.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: January 24, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Scott Banta, Oren Shur
  • Patent number: 9388447
    Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 12, 2016
    Assignee: AMGEN, INC.
    Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 9370182
    Abstract: A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: June 21, 2016
    Assignee: Toagosei Co., Ltd.
    Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida
  • Patent number: 9365844
    Abstract: Proteases encompassing an amino acid sequence that is at least 70% identical to the amino acid sequence indicated in SEQ ID NO. 1 over its entire length, and exhibit the amino acid substitution I21V in the count in accordance with SEQ ID NO. 1, agents that encompass such proteases, display very good cleaning performance on protease-sensitive stains.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 14, 2016
    Assignee: Henkel AG & Co. KGaA
    Inventors: Petra Siegert, Ulrich Schwaneberg, Ronny Martinez, Marion Merkel, Astrid Spitz, Susanne Wieland, Hendrik Hellmuth, Karl-Heinz Maurer
  • Patent number: 9175275
    Abstract: The invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: November 3, 2015
    Assignee: BP Corporation North America Inc.
    Inventors: Kevin A. Gray, Lishan Zhao, Michelle H. Cayouette
  • Patent number: 9109217
    Abstract: An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: August 18, 2015
    Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventor: Kenji Soejima
  • Publication number: 20150147783
    Abstract: The present invention relates to an isolated mutant eubacterium comprising at least one mutation resulting in a substitution of at least one amino acid in the beta-subunit of the RNA-polymerase encoded for by the rpoB-gene providing an altered production of a product of interest when said production of a product of interest is compared to the production of the same product in an isogenic wild type strain grown at identical conditions, wherein the substitution of at least one amino acid occurs at any of positions 469, 478, 482, 485, or 487 of SEQ ID NO:2, or at the equivalent positions in any eubacterial RNA-polymerase beta-subunit family member. Another aspect of the invention relates to a process for producing at least one product of interest in a mutant eubacterium and to a use of the mutant eubacterium according to the invention for producing at least one product of interest.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Steen Troels Joergensen, Jens Toenne Andersen, Niels Banke, Preben Nielsen
  • Patent number: 9040280
    Abstract: The present invention relates to proteases having at least 75% identity to a protease derived from Thermoascus aurantiacus and comprises at least one modification in the amino acid sequence thereof. These protease variants have improved thermostability. The invention also relates to DNA encoding these proteases, methods of their production, as well as the use thereof.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: May 26, 2015
    Assignee: NOVOZYMES A/S
    Inventors: Tomoko Matsui, Allan Noergaard, Thomas Agersten Poulsen, John Matthews
  • Publication number: 20150132825
    Abstract: The present invention provides methods for protein engineering and serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Applicant: DANISCO US INC.
    Inventors: Wolfgang Aehle, Luis G. Cascao-Pereira, David A. Estell, Frits Goedegebuur, James T. Kellis, JR., Ayrookaran J. Poulose, Brian F. Schmidt
  • Patent number: 9029115
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 12, 2015
    Assignees: Novozymes A/S, Novozymes Inc
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Publication number: 20150118356
    Abstract: A variant polypeptide having chymosin activity, wherein the variant has an amino acid sequence which, when aligned with the chymosin comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 2, 22, 40, 48, 50, 51, 53, 61, 62, 76, 88, 98, 99, 109, 112, 117, 125, 126, 135, 144, 160, 161, 163, 187, 189, 194, 200, 201, 202, 203, 221, 223, 240, 242, 244, 254, 267, 271, 273, 278, 280, 284, 289, 292, 294 or 295 said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered properties as compared with a reference polypeptide having chymosin activity. Such a variant polypeptide may be used in the preparation of a cheese.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Petrus Jacobus Theodorus Dekker, René Marcel De Jong, Cornelis Marinus Muijlwijk
  • Patent number: 9012390
    Abstract: Surfactants (e.g., fluorosurfactants) for stabilizing aqueous or hydrocarbon droplets in a fluorophilic continuous phase are presented. In some embodiments, fluorosurfactants include a fluorophilic tail soluble in a fluorophilic (e.g., fluorocarbon) continuous phase, and a headgroup soluble in either an aqueous phase or a lipophilic (e.g., hydrocarbon) phase. The combination of a fluorophilic tail and a headgroup may be chosen so as to create a surfactant with a suitable geometry for forming stabilized reverse emulsion droplets having a disperse aqueous or lipophilic phase in a continuous, fluorophilic phase. In some embodiments, the headgroup is preferably non-ionic and can prevent or limit the adsorption of molecules at the interface between the surfactant and the discontinuous phase. This configuration can allow the droplet to serve, for example, as a reaction site for certain chemical and/or biological reactions.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: April 21, 2015
    Assignee: Raindance Technologies, Inc.
    Inventors: Christian Holtze, David A. Weitz, John Brian Hutchison
  • Patent number: 8993256
    Abstract: The disclosure provides method and compositions for visualizing protein turnover. In particular, the disclosure provides methods and compositions useful for measuring the age of particular proteins or the dynamics of localized protein translation.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of California
    Inventors: Michael Z. Lin, Roger Y. Tsien
  • Patent number: 8993334
    Abstract: The present invention provides methods for separating proteins from a protein mixture. In one aspect, a method for separating a high concentration protein mixture into a bound protein fraction and a flow-through protein fraction can include delivering a protein mixture through an ion exchange column at a fixed pH and a fixed salt concentration. The fixed pH and the fixed salt concentration have been preselected to cause separation of the protein mixture into a bound protein fraction and a flow-through protein fraction. In this case, the bound protein fraction binds to the ion exchange column and the flow-though protein fraction flows though the ion exchange column. The method can further include receiving the flow-through protein fraction from the ion exchange column separate from the bound protein fraction, wherein either the bound protein fraction or the flow-through fraction contains a protein of interest.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: March 31, 2015
    Inventor: Anthony R. Torres
  • Publication number: 20150087066
    Abstract: The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: DARREL W. STAFFORD, TAO LI
  • Publication number: 20150079069
    Abstract: Methods for modification of mechanical properties or a shape of a mammalian tissue, excluding scar, blood clot, fat; including a step of contacting the tissue with an isolated eukaryotic endopeptidase in an amount sufficient to cause a modification of mechanical properties of the tissue or its shape, but insufficient to cause degradation of the tissue's into incohesive parts, and to the use of eukaryotic endopeptidases for use in methods for treatment of the mammalian body.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: ELASTOMICS AB
    Inventor: Aleksei Rozkov
  • Patent number: 8974843
    Abstract: Method of reducing the mTOR pathway stimulating activity of amino acid containing nutritional materials. This method comprises treating an enzymatically hydrolyzed protein material such as casein, whey, or soy protein with at least one enzyme capable of converting mTOR pathway stimulating amino acids and amino acid residues, such as leucine or methionine, into alternate chemical entities that do not stimulate or stimulate to a significantly lesser degree the mTOR pathway, while preserving the non-mTOR stimulating amino acids. These one or more alternate chemical entities should ideally be suitable for consumption, or alternatively be capable of being removed from the treated material through low cost extraction or conversion techniques. The material may then be sold as is, or alternatively packaged with low glycemic carbohydrates, healthy lipids, vitamins, and flavors and sold as a variety of different food products intended for an artificial diet intended to mimic the effects of caloric restriction.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 10, 2015
    Inventor: Ronald E. Rosedale
  • Patent number: 8962560
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: February 24, 2015
    Assignees: aTyr Pharma Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Publication number: 20150031114
    Abstract: The present invention relates to detergent compositions comprising subtilisin variants and methods for obtaining such detergent compositions. The present invention also relates to the use of such detergent compositions, especially in laundry or in hard surface cleaning applications.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 29, 2015
    Inventors: Werner Besenmatter, Astrid Benie, Marco Malten
  • Publication number: 20150030723
    Abstract: The present invention relates to a method for producing an acidified milk drink using an enzyme which reduces the isoelectric point of the milk proteins. The invention also relates to a novel enzyme having deamidase activity and its use in production of an acidified milk drink.
    Type: Application
    Filed: October 13, 2014
    Publication date: January 29, 2015
    Inventors: Jeppe Wegener Tams, Preben Nielsen
  • Publication number: 20150013024
    Abstract: Methods and constructs are provided for controlling processes in live animals, plants or microbes via genetically engineered near-infrared light-activated or light-inactivated proteins including chimeras including the photosensory modules of bacteriohytochromes and output modules that possess enzymatic activity and/or ability to bind to DNA, RNA, protein, or small molecules. DNA encoding these proteins are introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light of a different wavelength than the activating light. These proteins can regulate diverse cellular processes with high spatial and temporal precision, in a nontoxic manner, often using external light sources.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 8, 2015
    Applicant: UNIVERSITY OF WYOMING
    Inventors: Mark Gomelsky, Min-Hyung Ryu
  • Patent number: 8920828
    Abstract: Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also comprise one or more binders. The device can be an elongate solid body having a tapered or rounded insertion end. Alternatively, the device can include a plurality of particles. For devices containing multiple active agents, the configuration of the device be chosen to provide for the sequential or simultaneous release of each of the active agents. The elongate solid body can include a sheath comprising a first active agent and a core comprising a second active agent.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: December 30, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Hai H. Trieu
  • Publication number: 20140377836
    Abstract: The present invention relates to a crystal. In particular the present invention relates to a crystal of the N-domain of ACE protein. The present invention also relates to methods, processes, domain specific modulators, pharmaceutical compositions and uses of the N-domain crystal and the structure co-ordinates thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 25, 2014
    Applicants: UNIVERSITY OF BATH, UNIVERSITY OF CAPE TOWN
    Inventors: Ravi Acharya, Edward Sturrock
  • Patent number: 8916149
    Abstract: Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids. Also provided are methods of treating sepsis in a subject comprising administering to the subject one or more of the provided polypeptides or nucleic acids. Methods of screening for polypeptides with enhanced activated protein C and for an agent for treatment of sepsis are provided. Finally, provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: December 23, 2014
    Assignee: University of Rochester
    Inventor: Minsoo Kim
  • Patent number: 8906661
    Abstract: An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: December 9, 2014
    Assignee: The Chemo-Sero-Therapeutic Research Institute
    Inventor: Kenji Soejima
  • Patent number: 8906366
    Abstract: Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: December 9, 2014
    Assignee: NHS Blood and Transplant
    Inventors: Joanne Lloyd, Peter Feldman
  • Patent number: 8883456
    Abstract: The invention relates to a process of process of producing a fermentation product, comprising: liquefying a starch-containing material to dextrins with an alpha-amylase in the presence of a GH61 polypeptide; saccharifying the dextrins to a sugar with a glucoamylase; and fermenting the sugar using a fermenting organism.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: November 11, 2014
    Assignee: Novozymes North America, Inc.
    Inventors: Chee-Leong Soong, Jeremy Saunders
  • Patent number: 8865449
    Abstract: The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: October 21, 2014
    Assignee: Danisco US Inc.
    Inventors: Wolfgang Aehle, David A. Estell, Ronaldus W. J. Hommes, Brian E. Jones, Marc Kolkman, Chris Leeflang, Hiroshi Oh, Ayrookaran J. Poulose, Andrew Shaw, Wilhelmus A. H. Van der Kley, Leonardus P. M. Van Marrewijk
  • Patent number: 8865426
    Abstract: The object of the present invention is to provide a method for screening a substance that affects gelatinase-mediated EphA4 processing. The present invention provides a method for screening a substance that affects gelatinase-mediated EphA4 processing, which comprises the steps of: (a) allowing a first biological composition containing gelatinase or a biologically active fragment thereof to be contacted with a second biological composition containing EphA4 in the presence and absence of a candidate substance; (b) measuring the presence or amount of the EphA4 ectodomain and/or endodomain fragment; and (c) selecting the candidate substance as a substance that affects gelatinase-mediated EphA4 processing if the results of the step (b) measured in the presence of the candidate substance are changed in comparison with the results of the step (b) measured in the absence of the candidate substance.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: October 21, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Eiji Inoue
  • Publication number: 20140302582
    Abstract: The invention provides a chimeric E2 enzyme comprising a Ubc domain fused to a heterologous ubiquitin binding domain (UBD). The chimeric enzymes of the invention may be useful in producing elevated levels of free polyubiquitin.
    Type: Application
    Filed: May 13, 2014
    Publication date: October 9, 2014
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: David Komander, Anja Bremm
  • Publication number: 20140286963
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 25, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Publication number: 20140271607
    Abstract: A blood coagulation factor VII derivative, a blood coagulation factor VIIa derivative, FacVII and FacVIIa conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. FacVII and VIIa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacVII and FacVIIa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacVII and FacVIIa derivatives using the transformants, a method for preparing the FacVIIa conjugate and complex, a FacVIIa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 18, 2014
    Inventors: Dae Jin Kim, Byung Sun Lee, Sung Hwan Hong, Yong Ho Huh, Sung Youb Jung, Se Chang Kwon
  • Publication number: 20140273150
    Abstract: Provided herein are compositions and methods that can remove, metabolize, or degrade a hydrocarbon in an area that is contaminated by hydrocarbons. Methods for bioremediation of an area such as an area of land, a body of water, or a shoreline that are contaminated by a hydrocarbon, such as from a crude oil spill are also described. The compositions and methods described herein can be used on natural flora and fauna as well as manmade materials that are contaminated by a hydrocarbon.
    Type: Application
    Filed: July 23, 2013
    Publication date: September 18, 2014
    Inventor: Janet Angel
  • Patent number: 8828703
    Abstract: Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: September 9, 2014
    Assignee: Dyax Corp.
    Inventor: Robert C. Ladner
  • Publication number: 20140242036
    Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.
    Type: Application
    Filed: June 18, 2013
    Publication date: August 28, 2014
    Inventors: JOHN JAIRO MIRA CASTILLO, PAOLA ANDREA ZAPATA OCAMPO, LUCíA ATEHORTÚA GARCÉS, LIUDA JOHANA SEPÚLVEDA ARANGO, DIEGO FERNANDO ROJAS VAHOS
  • Publication number: 20140227764
    Abstract: Proteases that comprise an amino acid sequence that is at least 70% identical to the amino acid sequence indicated in SEQ ID NO. 1 over its entire length and that comprise, in the count in accordance with SEQ ID NO. 1, the amino acid substitution R99E or R99D in combination with at least two further amino acid substitutions that are selected from the group consisting of S3T, V4I, and V199I, display very good cleaning performance in particular on blood-containing stains, as well as very good temperature stability.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 14, 2014
    Applicant: Henkel AG & Co. KGaA
    Inventors: Hendrik Hellmuth, Marion Merkel, Brian Laufs, Susanne Wieland, Timothy O'Connell, Susanne Tondera, Thomas Weber
  • Patent number: 8802386
    Abstract: A method is provided for determining in real time the course of thrombin activity in a sample of blood or plasma as it appears in and disappears from the simple which comprises adding a thrombin substrate to the sample that, per unit time, produces a detectable signal in a quantity that bears relation to the amount of thrombin present. Simultaneously, in a control sample of the same blood or plasma in which thrombin generation is not triggered, the activity of a standard preparation with invariable thrombin activity is measured. The exact molar amount of thrombin present at any moment is obtained by comparison of the activity measured in clotting blood and the simultaneously measured calibrator. The method is useful inter alia for diagnosing hyper- and hypo-coaguable states, either congenital, acquired or drug-induced in humans and animals. Also provided is a kit for use in this method.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 12, 2014
    Assignee: Synapse B.V.
    Inventors: Peter Giesen, Hendrik Hemker, Raed Al Dieri, Suzette L. Beguin, Robert Wagenvoord